Eating less frequently may therefore result in fewer periods of meal-stimulated saliva, although it is not known whether this causes persistent dry mouth in GLP-1 users
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for the treatment of type 2 diabetes mellitus (under the brand name Mounjaro) and chronic weight management (as Zepbound)
Understanding whether semaglutide will work if tirzepatide does not is a real clinical question that many patients face
This has led to a surge in interest comparing tirzepatide, the reigning champion of metabolic pharmacotherapy, against retatrutide, the highly anticipated challenger
In APP/PS1 transgenic mice, (D-Ser2)Oxm, a dual GLP-1 and Gcg receptor agonist, notably improves spatial memory and synaptic plasticity, reduces A plaque deposition in the hippocampus, and modulates the PI3K/AKT1/GSK3 signaling pathway [84]
